Fully biodegradable versus nitinol occluder devices for transcatheter patent foramen ovale closure: a systematic review
Abstract
Background: The optimal device platform for transcatheter patent foramen ovale (PFO) closure remains uncertain. Permanent nitinol occluders are widely used, but concerns persist regarding long-term foreign-body exposure and device-related complications. Fully biodegradable occluders have been developed to provide temporary septal support during endothelialization before gradual resorption, with the intended benefit accruing only after the device has resorbed. Methods: We systematically searched Medline, PubMed, Embase, Scopus, Web of Science, the Cochrane Library, and trial registries through 17 February 2026. Eligible studies were randomized or comparative observational studies of patients aged 16 years or older undergoing PFO closure with biodegradable or bioresorbable versus nitinol or metallic occluders. Two reviewers independently screened studies and extracted data. Risk of bias was assessed using RoB 2 for randomized evidence and ROBINS-I for non-randomized evidence. Because of clinical and methodological heterogeneity, findings were synthesized narratively. Results: Three comparative studies were included-one randomized trial and two retrospective cohorts-comprising 481 analyzed participants. Procedural success was high with both device types. Residual shunt generally decreased over time, with no clear advantage for either platform. Serious adverse events, device thrombosis, embolization or detachment, and atrial arrhythmias were uncommon, though event counts were…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 481 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.